Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
LLY compared with AKBA: revenue, margins and what each company keeps, and the suppliers and customers both name
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
AKBA
Akebia Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
LLY
ELI Lilly & Co
vs
AKBA
Akebia Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Co-movers
Desk
News
Calendar
Saved
Search
Co-movers
daily closes
Method
›
Moved together
LLY
with
AKBA
Uncorrelated: r 0.14 · 499D.
No shared co-movers.
LLY, solid
AKBA, hatched
r = correlation
Bar = r to r 0.75
Source: daily closes
LLY
ELI Lilly & Co
Change
1,417.89
▲
+0.60%
· post 1,419.27
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
AKBA
Akebia Therapeutics, Inc.
Change
0.69
▼
−4.35%
· post 0.69
Closed
Nov 4 '26
Mkt cap
$192.5M
Revenue
$49M
Q2 FY26
Revenue
$236M
FY25
vs
Compare
Closed
Nov 4 '26
LLY
ELI Lilly & Co
vs
AKBA
Akebia Therapeutics, Inc.
1,417.89
▲
+0.60%
post 1,419.27
Price
0.69
▼
−4.35%
post 0.69
$1.3T
Mkt cap
$192.5M
Q3 FY26
$24.4B
Revenue
$49M
Q2 FY26
FY25
$65.2B
Revenue
$236M
FY25
Change
Change
LLY
1,417.89
▲
+0.60%
vs
AKBA
0.69
▼
−4.35%
Closed
Nov 4 '26